The government’s internal inter-agency machinery does the heavy lifting before industry is invited in. That upstream process shapes, narrows and will almost certainly set the terms under which any negotiation involving the industry can take place. It still creates opportunity.
A fraught process but also an opportunity to reintroduce ideas sidelined by the review
May 28, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Novo Nordisk backs care for rural health professionals in southern NSW
August 19, 2026 - - Latest News -
Opportunity #3 - finally deliver on the repeated claims of patient-centricity
August 19, 2026 - - Latest News -
Departmental restructure formally splits medicines financing from pharmacy services
August 19, 2026 - - Latest News -
Wesfarmers Health evolves its loyalty program with new Pulse Rewards
August 19, 2026 - -
CSL absorbs loss in reset year as investors back its plasma-led recovery
August 18, 2026 - - Latest News -
Opportunity #2 - AI can democratise HTA and the negotiations must not squander it
August 18, 2026 - - Latest News -
Opportunity #1 - biosimilar policy failure has become impossible to ignore
August 18, 2026 - - Latest News

